{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:52:07Z","timestamp":1788306727301,"version":"build-2803163510"},"reference-count":43,"publisher":"American Society of Hematology","issue":"9","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,14]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Hyperproliferation of myeloid and erythroid cells in myeloproliferative neoplasms (MPN) driven by the JAK2-V617F mutation is associated with altered metabolism. Given the central role of glutamine in anabolic and catabolic pathways, we examined the effects of pharmacologically inhibiting glutaminolysis, that is, the conversion of glutamine (Gln) to glutamate (Glu), using CB-839, a small molecular inhibitor of the enzyme glutaminase (GLS). We show that CB-839 strongly reduced the mitochondrial respiration rate of bone marrow cells from JAK2-V617F mutant (VF) mice, demonstrating a marked dependence of these cells on Gln-derived ATP production. Consistently, in\u00a0vivo treatment with CB-839 normalized blood glucose levels, reduced splenomegaly and decreased erythrocytosis in VF mice. These effects were more pronounced when CB-839 was combined with the JAK1\/2 inhibitor ruxolitinib or the glycolysis inhibitor 3PO, indicating possible synergies when cotargeting different metabolic and oncogenic pathways. Furthermore, we show that the inhibition of glutaminolysis with CB-839 preferentially lowered the proportion of JAK2-mutant hematopoietic stem cells (HSCs). The total number of HSCs was decreased by CB-839, primarily by reducing HSCs in the G1 phase of the cell cycle. CB-839 in combination with ruxolitinib also strongly reduced myelofibrosis at later stages of MPN. In line with the effects shown in mice, proliferation of CD34+ hematopoietic stem and progenitor cells from polycythemia vera patients was inhibited by CB-839 at nanomolar concentrations. These data suggest that inhibiting GLS alone or in combination with inhibitors of glycolysis or JAK2 inhibitors represents an attractive new therapeutic approach to MPN.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023010950","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T20:01:57Z","timestamp":1706731317000},"page":"2312-2325","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":25,"title":["The glutaminase inhibitor CB-839 targets metabolic dependencies of <i>JAK2<\/i>-mutant hematopoiesis in MPN"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4575-8029","authenticated-orcid":false,"given":"Marc","family":"Usart","sequence":"first","affiliation":[{"name":"1Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Hansen","sequence":"additional","affiliation":[{"name":"1Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4301-2856","authenticated-orcid":false,"given":"Jan","family":"Stetka","sequence":"additional","affiliation":[{"name":"1Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Almeida Fonseca","sequence":"additional","affiliation":[{"name":"1Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8727-4615","authenticated-orcid":false,"given":"Alexandre","family":"Guy","sequence":"additional","affiliation":[{"name":"1Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland"},{"name":"2UMR1034, Inserm, Biology of Cardiovascular Diseases, University of Bordeaux, Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1999-782X","authenticated-orcid":false,"given":"Quentin","family":"Kimmerlin","sequence":"additional","affiliation":[{"name":"1Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivam","family":"Rai","sequence":"additional","affiliation":[{"name":"1Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Hao-Shen","sequence":"additional","affiliation":[{"name":"1Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4192-5099","authenticated-orcid":false,"given":"Julien","family":"Roux","sequence":"additional","affiliation":[{"name":"3Bioinformatics core facility, Department of Biomedicine, University of Basel, Basel, Switzerland"},{"name":"4Swiss Institute of Bioinformatics, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Dirnhofer","sequence":"additional","affiliation":[{"name":"5Department of Pathology, University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3626-9496","authenticated-orcid":false,"given":"Radek C.","family":"Skoda","sequence":"additional","affiliation":[{"name":"1Experimental Hematology, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"issue":"7037","key":"2024051415260923300_bib1","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A\u00a0unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"17","key":"2024051415260923300_bib2","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A\u00a0gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024051415260923300_bib3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"9464","key":"2024051415260923300_bib4","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"5","key":"2024051415260923300_bib5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"2024051415260923300_bib6","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"10","key":"2024051415260923300_bib7","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"issue":"25","key":"2024051415260923300_bib8","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"2024051415260923300_bib9","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024051415260923300_bib10","first-page":"148","article-title":"The metabolism of carcinoma cells","volume":"9","author":"Warburg","year":"1925","journal-title":"J\u00a0Cancer Res"},{"issue":"1","key":"2024051415260923300_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cmet.2007.10.002","article-title":"The biology of cancer: metabolic reprogramming fuels cell growth and proliferation","volume":"7","author":"DeBerardinis","year":"2008","journal-title":"Cell Metab"},{"issue":"49","key":"2024051415260923300_bib12","doi-asserted-by":"crossref","first-page":"19345","DOI":"10.1073\/pnas.0709747104","article-title":"Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis","volume":"104","author":"DeBerardinis","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2024051415260923300_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"issue":"21","key":"2024051415260923300_bib14","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1182\/blood.2019000162","article-title":"JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms","volume":"134","author":"Rao","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2024051415260923300_bib15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1158\/1535-7163.MCT-07-0482","article-title":"Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth","volume":"7","author":"Clem","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"3168","key":"2024051415260923300_bib16","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1126\/science.122.3168.501","article-title":"Nutrition needs of mammalian cells in tissue culture","volume":"122","author":"Eagle","year":"1955","journal-title":"Science"},{"key":"2024051415260923300_bib17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0006-3002(60)90779-4","article-title":"Effect of anaerobiosis and addition of keto acids on glutamine utilization by Ehrlich ascites-tumor cells","volume":"42","author":"Kvamme","year":"1960","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"2024051415260923300_bib18","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1042\/bj0830284","article-title":"Glutamine metabolism in Ehrlich ascites-carcinoma cells","volume":"83","author":"Coles","year":"1962","journal-title":"Biochem J"},{"issue":"9","key":"2024051415260923300_bib19","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1172\/JCI69600","article-title":"Glutamine and cancer: cell biology, physiology, and clinical opportunities","volume":"123","author":"Hensley","year":"2013","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"2024051415260923300_bib20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/onc.2009.358","article-title":"Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer","volume":"29","author":"DeBerardinis","year":"2010","journal-title":"Oncogene"},{"issue":"1","key":"2024051415260923300_bib21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4062\/biomolther.2017.178","article-title":"Targeting glutamine metabolism for cancer treatment","volume":"26","author":"Choi","year":"2018","journal-title":"Biomol Ther (Seoul)"},{"issue":"pt 3","key":"2024051415260923300_bib22","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1042\/BJ20040996","article-title":"Co-expression of glutaminase K and L isoenzymes in human tumour cells","volume":"386","author":"Perez-Gomez","year":"2005","journal-title":"Biochem J"},{"issue":"4","key":"2024051415260923300_bib23","doi-asserted-by":"crossref","first-page":"514","DOI":"10.2174\/1566524011313040005","article-title":"Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer","volume":"13","author":"Mates","year":"2013","journal-title":"Curr Mol Med"},{"issue":"4","key":"2024051415260923300_bib24","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1535-7163.MCT-13-0870","article-title":"Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer","volume":"13","author":"Gross","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"18","key":"2024051415260923300_bib25","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.1158\/1078-0432.CCR-21-1204","article-title":"A\u00a0phase I dose-escalation and expansion study of telaglenastat in patients with advanced or metastatic solid tumors","volume":"27","author":"Harding","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"15","key":"2024051415260923300_bib26","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1158\/1078-0432.CCR-22-0061","article-title":"Telaglenastat plus everolimus in advanced renal cell carcinoma: a randomized, double-blinded, placebo-controlled, phase II ENTRATA Trial","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2024051415260923300_bib27","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1158\/1078-0432.CCR-21-2972","article-title":"Telaglenastat plus cabozantinib or everolimus for advanced or metastatic renal cell carcinoma: an open-label phase I trial","volume":"28","author":"Meric-Bernstam","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2024051415260923300_bib28","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice","volume":"111","author":"Tiedt","year":"2008","journal-title":"Blood"},{"issue":"7","key":"2024051415260923300_bib29","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1182\/blood-2004-08-3037","article-title":"In\u00a0vivo fate-tracing studies using the Scl stem cell enhancer: embryonic hematopoietic stem cells significantly contribute to adult hematopoiesis","volume":"105","author":"Gothert","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2024051415260923300_bib30","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1006\/cimm.2001.1895","article-title":"Observation of antigen-dependent CD8+ T-cell\/ dendritic cell interactions in\u00a0vivo","volume":"214","author":"Schaefer","year":"2001","journal-title":"Cell Immunol"},{"issue":"5","key":"2024051415260923300_bib31","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"14","key":"2024051415260923300_bib32","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"issue":"18","key":"2024051415260923300_bib33","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood-2015-09-670208","article-title":"Aryl hydrocarbon receptor-dependent enrichment of a megakaryocytic precursor with a high potential to produce proplatelets","volume":"127","author":"Strassel","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2024051415260923300_bib34","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/biostatistics\/kxw055","article-title":"Overcoming confounding plate effects in differential expression analyses of single-cell RNA-seq data","volume":"18","author":"Lun","year":"2017","journal-title":"Biostatistics"},{"issue":"1","key":"2024051415260923300_bib35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"issue":"3","key":"2024051415260923300_bib36","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/gb-2010-11-3-r25","article-title":"A\u00a0scaling normalization method for differential expression analysis of RNA-seq data","volume":"11","author":"Robinson","year":"2010","journal-title":"Genome Biol"},{"issue":"41","key":"2024051415260923300_bib37","doi-asserted-by":"crossref","first-page":"17413","DOI":"10.1073\/pnas.0909296106","article-title":"Resolving the distinct stages in erythroid differentiation based on dynamic changes in membrane protein expression during erythropoiesis","volume":"106","author":"Chen","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"2024051415260923300_bib38","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1182\/blood-2018-01-829036","article-title":"Glutamine via alpha-ketoglutarate dehydrogenase provides succinyl-CoA for heme synthesis during erythropoiesis","volume":"132","author":"Burch","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2024051415260923300_bib39","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/ncb3527","article-title":"Regulation of mitochondrial biogenesis in erythropoiesis by mTORC1-mediated protein translation","volume":"19","author":"Liu","year":"2017","journal-title":"Nat Cell Biol"},{"issue":"22","key":"2024051415260923300_bib40","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.4161\/cc.22632","article-title":"Glutaminolysis feeds mTORC1","volume":"11","author":"Duran","year":"2012","journal-title":"Cell Cycle"},{"issue":"11","key":"2024051415260923300_bib41","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2017.81","article-title":"High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells","volume":"31","author":"Poulain","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"2024051415260923300_bib42","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.stem.2020.03.003","article-title":"Differential alternative polyadenylation landscapes mediate hematopoietic stem cell activation and regulate glutamine metabolism","volume":"26","author":"Sommerkamp","year":"2020","journal-title":"Cell Stem Cell"},{"issue":"11","key":"2024051415260923300_bib43","doi-asserted-by":"crossref","first-page":"e0259241","DOI":"10.1371\/journal.pone.0259241","article-title":"The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma","volume":"16","author":"Emberley","year":"2021","journal-title":"PLoS One"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/9\/2312\/2225049\/blooda_adv-2023-010950-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/9\/2312\/2225049\/blooda_adv-2023-010950-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T15:26:31Z","timestamp":1715700391000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/9\/2312\/514787\/The-glutaminase-inhibitor-CB-839-targets-metabolic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,5,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010950","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,14]]}}}